PHC-HOLDINGS
3.9.2021 12:41:06 CEST | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global life science, diagnostics and medical device company, has today announced the appointment of William (Bill) Donnelly and Ivan Tornos as independent external directors, effective September 3, 2021. Both bring significant expertise and executive-level experience at global medical device and life sciences companies.
Mr. Donnelly joins the board with almost 25 years’ experience in the laboratory equipment industry. Mr. Donnelly was most recently the Executive Vice President responsible for Finance, Supply Chain, Manufacturing and IT for Mettler-Toledo. Prior to becoming Executive Vice President, he held various senior executive positions, including Group CFO and as a Global Business Leader for one of Mettler-Toledo’s Divisions. Prior to this he was Chief Financial Officer at Elsag Bailey Process Automation, a market leader in industrial instrumentation and systems for the process control industry. He started his career working as an auditor for Price Waterhouse for 10 years. He is currently an Independent Director of Ingersoll Rand and PST, as well as the Board Chair for John Carroll University.
Mr. Tornos joins the board with almost 25 years’ experience in the medical device industry. Mr. Tornos is currently the Chief Operating Officer at Zimmer Biomet, responsible for overseeing all global businesses and leading the global operations, clinical and medical education, and global R&D functions. Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics and was later Group President, Global Businesses and the Americas, before becoming COO earlier this year. Prior to joining Zimmer Biomet, Mr. Tornos was Worldwide President of the Global Urology Group, Medical, and Critical Care Divisions at Becton Dickinson Interventional. He has also held global senior leadership positions in commercial, business development and operations for Covidien International, Baxter International, Johnson & Johnson and Bausch & Lomb.
John Marotta, President, CEO and Chairman of the Board of Directors for PHCHD said, "I am thrilled to have Bill and Ivan join the PHC Holdings Board of Directors. These are two exceptional industry leaders who will add vast experience and capabilities to our board. We are a global company and have set out to add individuals to our board who have deep expertise and diverse perspectives that can help with all aspects of our business. Bill and Ivan’s industry knowledge and strategic guidance will be immensely valuable to the future success of the PHC Group."
Hiro Hirano, Co-Head of Private Equity for KKR Asia and CEO of KKR Japan Limited, and member of the Board of Directors for PHCHD, added, “We are excited about the addition of Bill and Ivan to the PHC Holdings Board of Directors. We have worked to assemble a board with a range of experiences in operational and financial disciplines, and these additions take the board a key step forward in expanding our capabilities. We believe we have the right mix of global leaders who can support the next chapter in the evolution of our business.”
The addition of these new independent external directors follows the recent appointment of Mr. Alan Malus and Ms. Kyoko (Kay) Deguchi in July 2021.
John Marotta added, "Diversity is a high priority for PHC Holdings and all of our operating companies. As we continue to evolve in our journey of diversity and inclusion, we will further evolve our Board of Directors as a part of this initiative.”
About PHC Holdings Corporation
PHC Holdings Corporation is a global healthcare company with subsidiaries including PHC Corporation, Ascensia Diabetes Care, Epredia, and LSI Medience Corporation. Committed to its corporate mission that states, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company develops, manufactures, sells and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The PHC Group’s consolidated net sales in FY2020 were 306 billion yen with global distribution of products and services in more than 125 countries.
www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005161/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom